Lytix Biopharma AS Cash Flow-to-Debt Ratio
Lytix Biopharma AS cash flow-to-debt ratio. Lytix Biopharma AS (LYTIX) has a Cash Flow-to-Debt Ratio of -3.03x as of December 2025, meaning its operating cash flow of Nkr-59.85 Million could theoretically repay -3% of its total liabilities (Nkr19.77 Million) in one year. See how financially flexible is Lytix Biopharma AS to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Lytix Biopharma AS (2017–2025)
Cash flow-to-debt ratio of Lytix Biopharma AS from 2017 to 2025. Historical debt coverage capacity for Lytix Biopharma AS across 9 annual periods. Check Lytix Biopharma AS cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Lytix Biopharma AS Cash Flow-to-Debt Ratio by Year (2017–2025)
Lytix Biopharma AS cash flow-to-debt ratio by year from 2017 to 2025. Year-by-year debt coverage analysis for Lytix Biopharma AS. For the full cash flow conversion analysis, see Lytix Biopharma AS (LYTIX) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (NOK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.03x | Nkr-59.85 Million | Nkr19.77 Million | ▼ -66.2% |
| 2024 | -1.82x | Nkr-70.37 Million | Nkr38.64 Million | ▲ +76.2% |
| 2023 | -7.64x | Nkr-95.97 Million | Nkr12.55 Million | ▼ -147.8% |
| 2022 | -3.08x | Nkr-52.10 Million | Nkr16.89 Million | ▲ +8.4% |
| 2021 | -3.37x | Nkr-44.90 Million | Nkr13.34 Million | ▼ -76.0% |
| 2020 | -1.91x | Nkr-24.35 Million | Nkr12.73 Million | ▲ +80.0% |
| 2019 | -9.55x | Nkr-36.82 Million | Nkr3.85 Million | ▼ -134.8% |
| 2018 | -4.07x | Nkr-72.62 Million | Nkr17.85 Million | ▼ -106.1% |
| 2017 | -1.97x | Nkr-69.67 Million | Nkr35.30 Million | — |